IL303592A - Compositions for treating dry age-related macular degeneration (amd) - Google Patents

Compositions for treating dry age-related macular degeneration (amd)

Info

Publication number
IL303592A
IL303592A IL303592A IL30359223A IL303592A IL 303592 A IL303592 A IL 303592A IL 303592 A IL303592 A IL 303592A IL 30359223 A IL30359223 A IL 30359223A IL 303592 A IL303592 A IL 303592A
Authority
IL
Israel
Prior art keywords
compound
alkyl
group
pct
pharmaceutically acceptable
Prior art date
Application number
IL303592A
Other languages
English (en)
Hebrew (he)
Original Assignee
Cognition Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognition Therapeutics Inc filed Critical Cognition Therapeutics Inc
Publication of IL303592A publication Critical patent/IL303592A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL303592A 2020-12-11 2021-12-10 Compositions for treating dry age-related macular degeneration (amd) IL303592A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063124695P 2020-12-11 2020-12-11
PCT/US2021/062850 WO2022125925A1 (en) 2020-12-11 2021-12-10 Compositions for treating dry age-related macular degeneration (amd)

Publications (1)

Publication Number Publication Date
IL303592A true IL303592A (en) 2023-08-01

Family

ID=81974688

Family Applications (1)

Application Number Title Priority Date Filing Date
IL303592A IL303592A (en) 2020-12-11 2021-12-10 Compositions for treating dry age-related macular degeneration (amd)

Country Status (10)

Country Link
US (1) US20240009168A1 (cg-RX-API-DMAC7.html)
EP (1) EP4259129A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023553414A (cg-RX-API-DMAC7.html)
KR (1) KR20230118158A (cg-RX-API-DMAC7.html)
CN (1) CN116867488A (cg-RX-API-DMAC7.html)
AU (1) AU2021396380A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200346A1 (cg-RX-API-DMAC7.html)
IL (1) IL303592A (cg-RX-API-DMAC7.html)
MX (1) MX2023006677A (cg-RX-API-DMAC7.html)
WO (1) WO2022125925A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015116923A1 (en) 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
ES3063712T3 (en) 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
ES2969373B2 (es) 2022-10-14 2025-02-06 Igen Biolab Group Ag Composicion obtenida de lisados de microorganismos probioticos para uso en el tratamiento y/o prevencion de las enfermedades degenerativas del ojo
WO2025122753A2 (en) * 2023-12-08 2025-06-12 Cognition Therapeutics, Inc. Compositions and methods for the treatment of niemann-pick disease
CN117945980A (zh) * 2024-01-24 2024-04-30 上海健康医学院 一种异吲哚硫亚胺类化合物及其制备和作为sigma-2受体抑制剂的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
EP1635805A4 (en) * 2003-06-12 2007-08-08 Ms Science Corp SIGMA RECEPTOR LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RE-ESTABLISHMENT
US7829562B2 (en) * 2003-06-12 2010-11-09 M's Science Corporation Sigma ligands for neuronal regeneration and functional recovery
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
BRPI0919920A2 (pt) * 2008-10-22 2016-02-16 Acucela Inc compostos para tratamento de doenças e desordens oftálmicas
US20110269779A1 (en) * 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
US20140378460A1 (en) * 2011-08-25 2014-12-25 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
WO2015116923A1 (en) * 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
ES3063712T3 (en) * 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
KR20220142477A (ko) * 2020-02-13 2022-10-21 카그니션 테라퓨틱스, 인코퍼레이티드 인지 저하 환자에서 아밀로이드 베타 단량체 수준을 감소시키는 방법

Also Published As

Publication number Publication date
KR20230118158A (ko) 2023-08-10
AU2021396380A1 (en) 2023-06-22
CA3200346A1 (en) 2022-06-16
CN116867488A (zh) 2023-10-10
EP4259129A4 (en) 2024-11-27
WO2022125925A1 (en) 2022-06-16
MX2023006677A (es) 2023-06-27
JP2023553414A (ja) 2023-12-21
US20240009168A1 (en) 2024-01-11
EP4259129A1 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
US20240009168A1 (en) Compositions for treating dry age-related macular degeneration (amd)
US10987400B2 (en) Methods for the treatment of glaucoma and age-related macular degeneration by a peptide D-TRP-AIB
US11981636B2 (en) Compositions for treating neurodegenerative diseases
EP3756665B1 (en) Interval therapy for the treatment of eye diseases
US20240165077A1 (en) Compositions and methods for treating neurologic diseases
KR20180094879A (ko) 망막 질환을 치료하기 위한 미라베그론
WO2025122753A2 (en) Compositions and methods for the treatment of niemann-pick disease
RU2792562C2 (ru) Композиции для лечения нейродегенеративных заболеваний
CA3061787C (en) Compositions for treating neurodegenerative diseases
WO2025163607A1 (en) Use of lecanemab in ophthalmological conditions
WO2022249942A1 (ja) 網膜の神経細胞の保護剤
KR20260049797A (ko) 경도 인지 장애 치료를 위한 병용 요법의 치료제 조성물 및 사용 방법
US20200237715A1 (en) COX-2 Inhibitors for the Treatment of Ocular Disease